[HTML][HTML] Is the canonical RAF/MEK/ERK signaling pathway a therapeutic target in SCLC?

S Cristea, J Sage - Journal of Thoracic Oncology, 2016 - Elsevier
The activity of the RAF/MEK/ERK signaling pathway is critical for the proliferation of normal
and cancerous cells. Oncogenic mutations driving the development of lung adenocarcinoma …

[HTML][HTML] Targeted drugs in small-cell lung cancer

M Santarpia, MG Daffinà, N Karachaliou… - … lung cancer research, 2016 - ncbi.nlm.nih.gov
In contrast to non-small-cell lung cancer (NSCLC), few advances have been made in
systemic treatment of small-cell lung cancer (SCLC) in recent years. Most patients are …

Cyclic protein tyrosine kinase inhibitors

J Das, R Padmanabha, P Chen, D Norris… - US Patent …, 2016 - Google Patents
(*) Notice: Subject to any disclaimer, the term of this 3,505,055 A 4/1970 von Schmeling et
al. patent is extended or adjusted under 35 3,547.917. A 12/1970 Kulka et al. USC 154 (b) …

Δ2-Troglitazone promotes cytostatic rather than pro-apoptotic effects in breast cancer cells cultured in high serum conditions

A Berthe, S Flament, S Grandemange, M Zaffino… - Cell Cycle, 2016 - Taylor & Francis
We have previously shown that Δ2-Troglitazone (Δ2-TGZ) displayed anticancer effects on
breast cancer cell lines grown in low serum conditions (1% fetal calf serum (FCS)). The …

Neuroendocrine Tumors of the Lung

F Khalil - … Tumors: Review of Pathology, Molecular and …, 2016 - Springer
Lung NETs are known to arise from bronchial Kulchitsky cells, but differ in terms of
histopathology. In this chapter, we discuss the pathogenesis of lung neuroendocrine tumors …

Pharmacological Inhibition of Intracellular Signaling Pathways in Radioresistant Anaplastic Thyroid Cancer

D Bulgin, A Podcheko - New Aspects in Molecular and Cellular …, 2016 - books.google.com
Anaplastic thyroid cancer (ATC) is highly aggressive and has a poor therapeutic response
and leads to high mortality. It has been shown that activation of intracellular c-Jun N-terminal …